Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum

BACKGROUND: Secukinumab is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated efficacy in the treatment of axial spondyloarthritis (axSpA, i.e., ankylosing spondylitis and non-radiographic axSpA) across various clinical trials. However, data of secukinumab in clinical pra...

Descripción completa

Detalles Bibliográficos
Autores principales: Sivera, Francisca, Núñez-Monje, Victoria, Campos-Fernández, Cristina, Balaguer-Trull, Isabel, Robustillo-Villarino, Montserrat, Aguilar-Zamora, Marta, Garijo-Bufort, Marta, López-Gómez, Juan Miguel, Peña-González, Carolina, de la Morena, Isabel, Bedoya-Sanchís, Diego, Yankova-Komsalova, Liliya, Conesa-Mateos, Arantxa, Martínez-Cristóbal, Anna, Navarro-Blasco, Francisco Javier, Senabre-Gallego, José Miguel, Alegre-Sancho, Juan José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213893/
https://www.ncbi.nlm.nih.gov/pubmed/37250652
http://dx.doi.org/10.3389/fmed.2023.1156557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213893/
https://www.ncbi.nlm.nih.gov/pubmed/37250652
http://dx.doi.org/10.3389/fmed.2023.1156557

Ejemplares similares